27.09.2010 • NewsLanxessPeople

Lanxess Announces Management Changes in 3 Business Units

There will be a change in management at three of the 13 business units of specialty chemicals company Lanxess. Dr. Hans-Georg Schmitt, head of the Basic Chemicals business unit (BAC), will retire as of Jan. 1. Schmitt has been in charge of Basic Chemicals since the formation of Lanxess.

Dr. Hubert Fink, currently head of the Semi-Crystalline Products business unit (SCP), will succeed Schmitt at the Basic Chemicals business unit at the turn of the year.

The successor to Dr. Fink as head of the SCP business unit is Dr. Michael Zobel, MBA. He will assume his new role as of Oct. 15. He is currently responsible for the Lanxess Ion Exchange Resins business unit (ION).

Dr. Zobel's position as head of ION will be taken over by Jean-Marc Vesselle at the same time. Vesselle is currently responsible for the global product management and strategic development of the business unit.

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.